03

Oct

Choosing the right CRO: Global or Local?Webinar

Your promising new drug is ready for clinical trials, so here’s a big question: should you be thinking locally... or globally? Choosing the right CRO can make or break clinical trial success. Irina Petrova MD, OCT Clinical director of clinical operations, will guide you by sharing insights.  

Read

05

Sep

Why Global CROs Outsource to Local CROs — and Why You Should, TooArticles

Sponsors often choose to work with global CROs when offshoring clinical trials, particularly for multinational studies.There are a few areas  however where local CROs can have a significant positive impact on a trial’s conduct.

Read

03

Sep

Phase III Erectile Dysfunction Clinical Study for Futura MedicalCase

OCT, Eastern Europe’s leading CRO, partners with UK-based Futura Medical completes clinical trial enrollment of 700 patients for MED2002, a topical gel developed to treat erectile dysfunction.

Read

30

Aug

What should you know before filing regulatory submissions for clinical trials in Russia?Articles

Find out about key components to be aware of when submitting study approvals for running clinical trials in Russia.

Read

07

Aug

Four Key Factors in Choosing a CROArticles

As the healthcare and life sciences industries have moved toward outsourcing models in clinical research, pharmaceutical and biotechnology companies face the challenge of finding the right Contract Research Organization (CRO) to assist in the clinical development of their treatments and medical devices. Although on the surface some services may seem similar, not all CROs are created equal.

Read

24

Jul

Rituximab biosimilar as first-line treatment for diffuse large B-cell lymphomaCase

A portfolio project for  mAbxience, where OCT Clinical Trials was responsible for all activities in Russia. Rituximab biosimilar as first-line treatment for diffuse large B-cell lymphoma.

Read

12

Jul

Clinical Research in Eastern Europe Articles

Irina Petrova, Director of Clinical Operations for OCT Clinical Trials, explores why U.S. and other international companies are turning to Russia as a clinical research destination.

Read

02

Jul

Why do US sponsors come to Russia? Discover new options for clinical trialsWebinar

Find out why more than 50% of studies initiated in Russia are conducted by foreign sponsors with the US in the lead. Key experts from one of the major local CROs in Eastern Europe will share exclusive insights on 3 critical benefits of the region to advance your clinical strategy.

Read

05

Jun

Interim Analysis as a Key Decision-Making ToolArticles

Good Clinical Practice dictates stricter compliance with the fundamental concepts of conducting interim analysis by Russian pharmaсeutical companies, mainly because of the additional organizational resources it requires. On the other hand, the methodology and principles of deciding on the necessity of carrying out an interim analysis are not always properly reflected in a research protocol.

Read

29

Mar

Russia Opens the Door for Stem Cell Clinical TrialsArticles

While the US, Europe and some Asian countries have had a fully functional, comprehensive regulatory platform for BCP procedures for over two decades, Russia is relatively new to the area, only recently approving a regulatory framework.

Read

04

Oct

Patterns of collaboration between medical writers and biostatisticians Articles

The Russian clinical trial industry and Russia’s local regulatory requirements are developing rapidly. Within Russian contract research organisations, medical writers must take on non-traditional roles and, in particular, must collaborate closely with biostatisticians within their organizations.

Read

11

Apr

Bioequivalence study of a drug for HIV patientsCase

An open-label, randomize, two-period, crossover study in healthy volunteers. Over 90% of volunteers were enrolled during the first two weeks. The target enrollment rates were reached within 21 days

Read

13

Nov

Nonclinical studies in the Russian FederationArticles

Drug product developers and sponsors face a number of problems when organizing a nonclinical study in Russia, especially, the diverse range of standards and few certified animal breeding centers, complicating adaptation of the available experimental data to domestic legislation.

Read